Journal of Autism and Developmental Disorders

, Volume 26, Issue 2, pp 231–235 | Cite as

Brief report: Psychopharmacology of autism spectrum disorders

  • Mark H. Lewis
Brief Reports


The purpose of this paper is to review briefly recent findings on the efficacy of psychopharmacological interventions in autism spectrum disorder, point out gaps in our current knowledge of the effects of specific drug classes, and suggest both general and specific research directions for the future. For a more comprehensive review of drug studies in autism, readers are directed toward McDougle, Price, and Volkmar (1994).


Autism Spectrum Disorder Current Knowledge Spectrum Disorder Drug Study School Psychology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aman, M. G., & Kern, R. A. (1989). Review of fenfluramine in the treatment of the developmental disabilities.Journal of the American Academy of Child and Adolescent Psychiatry, 28, 549–565.Google Scholar
  2. Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., & Sachar, E. J. (1978). A comparison of halperidol and behavior therapy and their interaction in autistic children.Journal of the American Academy of Child Psychiatry, 17, 640–655.Google Scholar
  3. Campbell, M., Anderson, L., Small, A., Adams, P., Gonzalez, N., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning.Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1283–1291.Google Scholar
  4. Chamberlain, R. S., & Herman, B. H. (1990). A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism.Biological Psychiatry, 28, 773–793.Google Scholar
  5. Cook, E. H. J., Rowlett, R., Jaselskis, C., & Leventhal, B. L. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation.Journal of the American Academy of Child and Adolescent Psychiatry, 31, 739–745.Google Scholar
  6. Gillberg, C. (1995). Endogenous opioids and opiate antagonists in autism: Brief review of empirical findings and implications for clinicians.Developmental Medicine and Child Neurology, 37, 239–245.Google Scholar
  7. Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., & Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine.American Journal of Psychiatry, 149, 363–366.Google Scholar
  8. Lewis, M. H., Bodfish, J. W., Powell, S. B., & Golden, R. N. (1995). Clomipramine treatment for repetitive movement disorders in mental retardation: A double-blind comparison with placebo.American Journal on Mental Retardation, 100, 299–312.Google Scholar
  9. Lewis, M. H., Gluck, J. P., Bodfish, J. W., Beauchamp, A. J., Beauchamp, A. J., & Mailman, R. B. (in press). Neurobiological basis of stereotyped movement disorder in animals and humans. In R. L. Sprague & K. M. Newell (Eds.),Stereotypy: Brain behavior relationships. Washington, DC:American Psychological Association.Google Scholar
  10. McDougle, C. J., Price, L. H., & Volkmar, F. R. (1994). Recent advances in the pharmacotherapy of autism and related conditions.Child and Adolescent Psychiatric Clinics of North America, 3, 71–89.Google Scholar
  11. McDougle, C. J., Price, L. H., Volkmar, F. R., Goodman, W. K., Ward-O'Brien, D., Nielsen, J., Bregman, J., & Cohen, D. J. (1992). Clomipramine in autism: Preliminary evidence of efficacy.Journal of the American Academy of Child and Adolescent Psychiatry, 31, 746–750.Google Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Mark H. Lewis
    • 1
  1. 1.Health Science CenterUniversity of FloridaGainsville

Personalised recommendations